Objectives To assess the effectiveness and safety of tocilizumab, a humanised anti‐
interleukin‐6 receptor antibody, in the treatment of critical or severe coronavirus disease …

Introduction: Tocilizumab, can be used in the treatment of COVID-19 in patients developing
cytokine storms. This study retrospectively evaluated patients treated with Tocilizumab …

Background The virological and immunological effects of the immunomodulatory drugs used
for COVID-19 remain unknown. We evaluated the impact of interleukin (IL)-6 blockade with …

Tocilizumab (TCZ), a monoclonal antibody against interleukin‐6 (IL‐6), emerged as an
alternative treatment for COVID‐19 patients with a risk of cytokine storms recently. In the …

Abstract Coronavirus disease 2019 (COVID‐19) can lead to a massive cytokine release. The
use of the anti‐interleukin‐6 receptor monoclonal antibody tocilizumab (TCZ) has been …

Severe COVID-19 pneumonia is a principal cause of death due to cascade of hyper
inflammatory condition that leading to lung damage. Therefore, an effective therapy to …

Background Controversy remains about the efficacy of tocilizumab (TCZ) for the treatment of
severe COVID-19. We aimed to analyze the profile of TCZ-respondent patients. Methods We …

Cytokine storm seems to be one of the main culprits for developing a severe form of COVID-
19, IL-6 being one of its basic components. Therefore, currently, tocilizumab is widely …

Background. Cytokine release syndrome can be observed during the course of COVID‐19.
Tocilizumab is used for treating this highly fatal syndrome. We think that the starting time of …

Background Severe and critical COVID-19 disease is characterized by hyperinflammation
involving pro-inflammatory cytokines, particularly IL-6. Tocilizumab is a monoclonal antibody …